Price
$27.96-22.16%Social Signal Score
Analyst Ratings
10 analystsRevenue
$3.70MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Harvey Davidson Facp.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 0.09
- Country
- NL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 20.36
Financials
Revenue
$3.70M-92.8%Net Income
$-64.14MEBITDA
$-59.69MFree Cash Flow
$-39.29MEPS (diluted)
$-0.52Shares Outstanding (diluted)
123.37M+43.2%Operating Expenses
$68.56MCash & Debt
$633.85MRevenue by Segment (annual)
$93.50MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $22.50M | $-203.82M | $-1.75 |
| 2024 | $45.56M | $-241.60M | $-2.56 |
| 2023 | $14.09M | $-176.94M | $-2.15 |
| 2022 | $102.69M | $-22.63M | $-1.19 |
| 2021 | $0.00 | $-41.78M | $-3.34 |
| 2020 | $0.00 | $-7.02M | $0.00 |
Valuation
NAMShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·7d ago·Neutral
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer's disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIA
View source ↗ - Newsglobenewswire.com·15d ago·Negative
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
…he European Society of Cardiology (ESC) Congress 2026 NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today annou…
View source ↗ - Newsseekingalpha.com·58d ago·Positive
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.50 per share
Typical surprise -8.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.52 vs $-0.48miss
- Thu, May 7$-0.40 vs $-0.46beat
- Wed, Feb 18$-0.63 vs $-0.43miss
- Wed, Nov 5$-0.61 vs $-0.38miss
- Wed, Aug 6$-0.15 vs $-0.52beat
- Thu, May 8$-0.49 vs $-0.45miss
Estimates and results for NAMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NAMS officers and directors.
- Bought
- $227k
- Sold
- $57.6m
1 trade
37 trades
- Kastelein Johannes Jacob Pietersold
- Davidson Michael H.bought
- Smither John Wsold
- Kastelein Johannes Jacob Pietersold
- Kooij Louise Frederikasold
- Kooij Louise Frederikasold
- Kooij Louise Frederikasold
- Kooij Louise Frederikasold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NAMS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.